Fuminori Yoshida remarks
Regarding the release of the video of the interim financial results briefing
Message from Representative Director President and CEO Fuminori Yoshida
As announced, the Company announced its financial results for the second quarter of the fiscal year ending December 31, 2021 on Wednesday, August 4, and held an interim financial results briefing on Thursday, August 5. Despite the resurgence of the new corona infection, this time, in addition to 45 analysts and institutional investors (16 of whom were in attendance), 22 individual shareholders selected by lottery and a large number of people Thank you very much for your participation.
Today, with the release of the video of the interim financial results briefing, I would like to summarize my message at the briefing about three points.
- Although it was expected that the single-month PL in June of this year turned profitable, it is an extremely meaningful milestone achievement from a business perspective. Simply hiring sales staff and creating an organization will not lead to sales, but in order for a clock to tell the correct time, all the parts and gears must mesh precisely to keep the correct time. The fact that we achieved profitability in single-month PL in June was 2 years and 9 months after we announced the shift to our own sales system in October 2018, and our own sales organization began to generate productivity. This is nothing but testimony.
- We have been considering the return to profitability of the PL for the month of June as a touchstone for the success or failure of our business in the current fiscal year, and from June, we expect a reasonable amount of sales due to the full-scale treatment of DLBCL indications with the launch of P-BR by Chugai, in addition to our BR120 launched in April. We are already getting a sense of this. Therefore, even though there may be month-to-month fluctuations, we recognize that from this point on, our business performance will continue to rise steadily and that the question is not whether or not our business will turn profitable, but rather how much of a profit margin we can accumulate.
- We continue to be concerned about the impact of the resurgence of COVID-19 infections and delays in treatment due to vaccination among the elderly on our business performance. Due to the positive factors of the expected DLBCL indication sales, it is fully possible to overcome these problems, and there is no change to the operating income forecast of 1.36 billion yen for this fiscal year.
August 10, 2021
Representative Director President and CEO
Fuminori Yoshida